Eloralintide (LY3841136)

Eloralintide is the most interesting obesity molecule in development and one of the worst things you could actually buy right now, and both statements follow from the same fact: it has one excellent trial and nothing else. The weight loss is real and large, the tolerability profile is better than anything in the incretin class, and the receptor argument for why that should be true is published and quantified rather than a marketing line. None of that survives contact with the practical question. There is no legal supply, no data past 48 weeks, no published measurement of muscle preservation, and an unexplained slow-heart-rate signal that phase 3 will either dissolve or turn into a real caution, alongside a published and still unanswered question about whether this class switches on the renin-angiotensin system (Muskiet et al. 2026). Wait for the 2028 readout, or get into a trial.

✅ Best for: People with class 2 or class 3 obesity, matching the mean BMI of 39.1 in the trial population, who can enrol in one of the five recruiting phase 3 studies and get supervised access to the drug for free. People who stopped an incretin drug specifically because of nausea or food aversion, since the mechanism eloralintide uses is the one most likely to avoid that, and who are willing to wait for approval rather than improvise. Clinicians and researchers tracking the amylin class who need a reference point for where selective monotherapy currently sits. Anyone deciding between amylin and incretin routes who wants the comparison grounded in what has actually been measured rather than what is being promised.

❌ Avoid if: You are considering buying research-chemical powder, which is the only non-trial route and carries no purity guarantee, no dose verification and no recourse. You use mealtime insulin or a sulfonylurea, since the one boxed warning in the entire amylin class is severe low blood sugar in that combination. You have confirmed gastroparesis, an absolute contraindication on the pramlintide label and a mechanistic certainty for any drug that slows stomach emptying. You are pregnant, trying to conceive or breastfeeding, since no safety data exists. You take oral medication where timing matters, including contraceptives and antibiotics, because delayed stomach emptying delays absorption. You have a resting heart rate already on the low side, until the bradycardia observation is explained.